BRPI0511624A - antibodies and related molecules that bind to psca proteins - Google Patents

antibodies and related molecules that bind to psca proteins

Info

Publication number
BRPI0511624A
BRPI0511624A BRPI0511624-4A BRPI0511624A BRPI0511624A BR PI0511624 A BRPI0511624 A BR PI0511624A BR PI0511624 A BRPI0511624 A BR PI0511624A BR PI0511624 A BRPI0511624 A BR PI0511624A
Authority
BR
Brazil
Prior art keywords
psca
antibodies
bind
related molecules
variants
Prior art date
Application number
BRPI0511624-4A
Other languages
Portuguese (pt)
Inventor
Jean Gudas
Aya Jakobovits
Xiao-Chi Jia
Robert Kendall Morrison
Karen Jane Meyrick Morrison
Hui Shao
Pia M Challita-Eid
Arthur B Raitano
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/857,484 external-priority patent/US7622564B2/en
Application filed by Agensys Inc filed Critical Agensys Inc
Priority claimed from PCT/US2005/017412 external-priority patent/WO2005118864A2/en
Publication of BRPI0511624A publication Critical patent/BRPI0511624A/en
Publication of BRPI0511624B1 publication Critical patent/BRPI0511624B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Abstract

ANTICORPOS E MOLéCULAS RELACIONADAS QUE SE LIGAM à PROTEìNAS DE PSCA. A presente invenção refere-se a anticorpos e moléculas derivados dos mesmos que ligam a nova proteína de PSCA, e variantes das mesmas, em que PSCA apresenta expressão tecido específica em tecido adulto normal, e é expressado de modo aberrante nos cânceres listados na Tabela 1. Conseqüentemente, PSCA proporciona um alvo diagnóstico, prognóstico, profilático e/ou terapêutico para câncer. O gene PSCA ou fragmento do mesmo, ou sua proteína codificada, ou variantes da mesma, ou um framento da mesma, podem ser usados para provocar uma reação imune humoral ou celular; anticorpos ou células T reativas com PSCA podem ser usados em imunização ativa ou passiva.Antibodies and related molecules that bind to PSCA PROTEINS. The present invention relates to antibodies and molecules derived therefrom which bind the novel PSCA protein, and variants thereof, wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table 1. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and / or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, may be used to elicit a humoral or cellular immune reaction; PSCA-reactive antibodies or T cells can be used for active or passive immunization.

BRPI0511624-4A 2004-05-28 2005-05-17 MONOCLONAL ANTIBODY THAT BINDS TO PSCA PROTEIN, USE OF IT, HYBRIDOMA, VECTOR, PHARMACEUTICAL COMPOSITION, AS WELL AS ASSAY AND METHOD FOR DETECTION OF THE PRESENCE OF A PSCA PROTEIN IN A BIOLOGICAL SAMPLE BRPI0511624B1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US10/857,484 US7622564B2 (en) 2003-05-30 2004-05-28 Prostate stem cell antigen (PSCA) variants and subsequences thereof
PCT/US2004/017231 WO2005014780A2 (en) 2003-05-30 2004-05-28 Prostate stem cell antigen (psca) variants and subsequences thereof
US61638104P 2004-10-05 2004-10-05
US60/616,381 2004-10-05
US61788104P 2004-10-12 2004-10-12
US60/617,881 2004-10-12
US62131004P 2004-10-21 2004-10-21
US60/621,310 2004-10-21
US63307704P 2004-12-02 2004-12-02
US60/633,077 2004-12-02
US67200005P 2005-04-14 2005-04-14
US60/672,000 2005-04-14
PCT/US2005/017412 WO2005118864A2 (en) 2004-05-28 2005-05-17 Antibodies and related molecules that bind to psca proteins

Publications (2)

Publication Number Publication Date
BRPI0511624A true BRPI0511624A (en) 2008-01-02
BRPI0511624B1 BRPI0511624B1 (en) 2022-02-08

Family

ID=44210117

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0511624-4A BRPI0511624B1 (en) 2004-05-28 2005-05-17 MONOCLONAL ANTIBODY THAT BINDS TO PSCA PROTEIN, USE OF IT, HYBRIDOMA, VECTOR, PHARMACEUTICAL COMPOSITION, AS WELL AS ASSAY AND METHOD FOR DETECTION OF THE PRESENCE OF A PSCA PROTEIN IN A BIOLOGICAL SAMPLE
BR122018073034-0A BR122018073034B1 (en) 2004-05-28 2005-05-17 ANTIBODIES AND RELATED MOLECULES THAT BIND TO PSCA PROTEINS

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122018073034-0A BR122018073034B1 (en) 2004-05-28 2005-05-17 ANTIBODIES AND RELATED MOLECULES THAT BIND TO PSCA PROTEINS

Country Status (6)

Country Link
KR (2) KR101282396B1 (en)
CN (1) CN102344493B (en)
BR (2) BRPI0511624B1 (en)
IL (1) IL214210A (en)
NO (1) NO341404B1 (en)
SI (1) SI1753871T1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
SG10201701424QA (en) * 2012-08-23 2017-04-27 Agensys Inc Antibody drug conjugates (adc) that bind to 158p1d7 proteins
KR20210088741A (en) * 2012-12-13 2021-07-14 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Dna antibody constructs and method of using same
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
CN105829341A (en) 2013-12-13 2016-08-03 宾夕法尼亚大学理事会 DNA antibody constructs and method of using same
CN107427566B (en) 2014-12-01 2021-08-17 宾夕法尼亚大学理事会 DNA antibody constructs and methods of use thereof
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6258939B1 (en) * 1997-03-10 2001-07-10 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
NZ337413A (en) * 1997-03-10 2003-02-28 Univ California Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
IL149116A0 (en) * 1999-10-29 2002-11-10 Genentech Inc Anti-prostate stem cell antigen (psca) antibody compositions and methods of use

Also Published As

Publication number Publication date
CN102344493A (en) 2012-02-08
KR101282396B1 (en) 2013-07-04
SI1753871T1 (en) 2016-01-29
NO20110647L (en) 2006-12-19
KR101215611B1 (en) 2012-12-28
IL214210A (en) 2013-01-31
BR122018073034B1 (en) 2021-10-13
NO341404B1 (en) 2017-10-30
KR20070047251A (en) 2007-05-04
BR122018073034B8 (en) 2022-10-11
KR20110056564A (en) 2011-05-30
BRPI0511624B1 (en) 2022-02-08
CN102344493B (en) 2014-09-03
IL214210A0 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
BRPI0418766A (en) antibodies and molecules derived from these that bind to steap-1 proteins
BRPI0410842A (en) prostate stem cell antigens (psca) variants and sub-sequences thereof
BRPI0511624A (en) antibodies and related molecules that bind to psca proteins
BR0112542A (en) Compositions and methods for ovarian cancer therapy and diagnosis
WO2009033094A3 (en) Antibodies and related molecules that bind to 24p4c12 proteins
WO2005118864A3 (en) Antibodies and related molecules that bind to psca proteins
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
CY1113247T1 (en) NUCLEAR ACIDS WITH THE TITLE 273P4B7 AND USE IN CANCER TEST
HUP0500345A2 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
ATE353974T1 (en) METHODS, COMPOSITIONS AND KITS FOR IDENTIFYING AND MONITORING BREAST CANCER
ATE486938T1 (en) C-TYPE LECTIN TRANSMEMBRANE ANTIGEN EXPRESSED IN HUMAN PROSTATE CANCER AND USES OF THIS ANTIGEN
WO2002078526A3 (en) Cancer-testis antigens
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
BR9914161A (en) Methods to detect the presence of breast cancer cells and endometrial cancer cells and the presence of breast cancer and endometrial cancer in a patient and kits to detect the presence of breast cancer cells and the presence of breast cancer in a sample
BRPI0407031A (en) Compositions and methods for cancer treatment using igsf9 and liv-1
EP1778284A4 (en) Nucleic acids and corresponding proteins entitled 58p1d12 useful in treatment and detection of cancer
WO2004040312A3 (en) Method for ngf assay for in vitro diagnosis of breast cancer and therapeutic use
DK1573022T3 (en) Nucleic acid and corresponding protein designated 184P1E2 suitable for the treatment and detection of cancer
BR9708005A (en) Down regulation resistant convertase C3
AR029547A1 (en) COMPOSITIONS AND METHODS FOR CANCER DE PULMON THERAPY AND DIAGNOSIS
ATE501255T1 (en) 84P2A9: PROSTATE AND TESTIS SPECIFIC PROTEIN THAT IS VERY HIGH IN PROSTATE CANCER
IL149045A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
NO20075592L (en) Antibodies and related molecules that bind to PSCA Proteins
MXPA05002520A (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/05/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.